Literature DB >> 32436268

N-benzhydryl quinuclidine compounds are a potent and Src kinase-independent inhibitor of NALCN channels.

Suyun Hahn1, So Woon Kim1, Ki Bum Um1, Hyun Jin Kim1,2, Myoung Kyu Park1,2.   

Abstract

BACKGROUND AND
PURPOSE: NALCN is a Na+ leak, GPCR-activated channel that regulates the resting membrane potential and neuronal excitability. Despite numerous possible roles for NALCN in both normal physiology and disease processes, lack of specific blockers hampers further investigation. EXPERIMENTAL APPROACH: The effect of N-benzhydryl quinuclidine compounds on NALCN channels was demonstrated using whole-cell patch-clamp recordings in HEK293T cells overexpressing NALCN and acutely isolated nigral dopaminergic neurons that express NALCN endogenously. Src kinase activity was measured using a Src kinase assay kit, and voltage and current-clamp recordings from nigral dopaminergic neurons were used to measure NALCN currents and membrane potentials. KEY
RESULTS: N-benzhydryl quinuclidine compounds inhibited NALCN channels without affecting TRPC channels, another important route for Na+ leak. In HEK293T cells overexpressing NALCN, N-benzhydryl quinuclidine compounds potently suppressed muscarinic M3 receptor-activated NALCN currents. Structure-function relationship studies suggest that the quinuclidine ring with a benzhydryl group imparts the ability to inhibit NALCN currents regardless of Src family kinases. Moreover, N-benzhydryl quinuclidine compounds inhibited not only GPCR-activated NALCN currents but also background Na+ leak currents and hyperpolarized the membrane potential in native midbrain dopaminergic neurons that express NALCN endogenously. CONCLUSION AND IMPLICATIONS: These findings suggest that N-benzhydryl quinuclidine compounds have a pharmacological potential to directly inhibit NALCN channels and could be a useful tool to investigate functions of NALCN channels.
© 2020 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32436268      PMCID: PMC7402281          DOI: 10.1111/bph.15104

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  The wake-promoting hypocretin-orexin neurons are in an intrinsic state of membrane depolarization.

Authors:  Emmanuel Eggermann; Laurence Bayer; Mauro Serafin; Benoît Saint-Mleux; Laurent Bernheim; Danièle Machard; Barbara E Jones; Michel Mühlethaler
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

Review 2.  Hyperpolarization-activated cation currents: from molecules to physiological function.

Authors:  Richard B Robinson; Steven A Siegelbaum
Journal:  Annu Rev Physiol       Date:  2002-11-19       Impact factor: 19.318

Review 3.  Mechanisms of regulation of neurotensin receptors.

Authors:  E Hermans; J M Maloteaux
Journal:  Pharmacol Ther       Date:  1998-08       Impact factor: 12.310

4.  Critical roles of Gi/o proteins and phospholipase C-δ1 in the activation of receptor-operated TRPC4 channels.

Authors:  Dhananjay P Thakur; Jin-bin Tian; Jaepyo Jeon; Jian Xiong; Yu Huang; Veit Flockerzi; Michael X Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

Review 5.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

Authors:  Stephen P H Alexander; Doriano Fabbro; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2019-12       Impact factor: 8.739

6.  Genetic analysis of mouse strains with variable serum sodium concentrations identifies the Nalcn sodium channel as a novel player in osmoregulation.

Authors:  Anne P Sinke; Christina Caputo; Shirng-Wern Tsaih; Rong Yuan; Dejian Ren; Peter M T Deen; Ron Korstanje
Journal:  Physiol Genomics       Date:  2010-12-21       Impact factor: 3.107

7.  TRPC7 is a receptor-operated DAG-activated channel in human keratinocytes.

Authors:  Benjamin Beck; Alexander Zholos; Vadym Sydorenko; Morad Roudbaraki; V'yacheslav Lehen'kyi; Pascal Bordat; Natalia Prevarskaya; Roman Skryma
Journal:  J Invest Dermatol       Date:  2006-06-01       Impact factor: 8.551

8.  Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor.

Authors:  M A Cascieri; E Ber; T M Fong; S Sadowski; A Bansal; C Swain; E Seward; B Frances; D Burns; C D Strader
Journal:  Mol Pharmacol       Date:  1992-09       Impact factor: 4.436

9.  The leak channel NALCN controls tonic firing and glycolytic sensitivity of substantia nigra pars reticulata neurons.

Authors:  Andrew Lutas; Carolina Lahmann; Magali Soumillon; Gary Yellen
Journal:  Elife       Date:  2016-05-13       Impact factor: 8.140

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  3 in total

1.  N-benzhydryl quinuclidine compounds are a potent and Src kinase-independent inhibitor of NALCN channels.

Authors:  Suyun Hahn; So Woon Kim; Ki Bum Um; Hyun Jin Kim; Myoung Kyu Park
Journal:  Br J Pharmacol       Date:  2020-06-17       Impact factor: 8.739

2.  TRPC3 and NALCN channels drive pacemaking in substantia nigra dopaminergic neurons.

Authors:  Ki Bum Um; Suyun Hahn; So Woon Kim; Yoon Je Lee; Lutz Birnbaumer; Hyun Jin Kim; Myoung Kyu Park
Journal:  Elife       Date:  2021-08-19       Impact factor: 8.140

3.  SLO2.1/NALCN a sodium signaling complex that regulates uterine activity.

Authors:  Juan J Ferreira; Chinwendu Amazu; Lis C Puga-Molina; Xiaofeng Ma; Sarah K England; Celia M Santi
Journal:  iScience       Date:  2021-10-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.